Evidence map›Paper›PMID 35011410›Full record

ArticleMolecules (Basel, Switzerland)2021

Evaluation of Virtual Screening Strategies for the Identification of γ-Secretase Inhibitors and Modulators.

Alicia Ioppolo, Melissa Eccles, David Groth, Giuseppe Verdile, Mark Agostino

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alicia IoppoloCurtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia.
Melissa EcclesCurtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia.
David GrothCurtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia.
Giuseppe VerdileCurtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia.
Mark AgostinoCurtin Health and Innovation Research Institute, Curtin Medical School, Curtin University, Bentley, WA 6102, Australia.ORCID 0000-0002-1799-0392
Curtin University · AUEdith Cowan University · AU

Funding

Curtin University CRF130006Dementia Australia Research Foundation PhD ScholarshipRaine Medical Research Foundation Raine Priming Grant
6 · The paper itself

Abstract

γ-Secretase is an intramembrane aspartyl protease that is important in regulating normal cell physiology via cleavage of over 100 transmembrane proteins, including Amyloid Precursor Protein (APP) and Notch family receptors. However, aberrant proteolysis of substrates has implications in the progression of disease pathologies, including Alzheimer's disease (AD), cancers, and skin disorders. While several γ-secretase inhibitors have been identified, there has been toxicity observed in clinical trials associated with non-selective enzyme inhibition. To address this, γ-secretase modulators have been identified and pursued as more selective agents. Recent structural evidence has provided an insight into how γ-secretase inhibitors and modulators are recognized by γ-secretase, providing a platform for rational drug design targeting this protease. In this study, docking- and pharmacophore-based screening approaches were evaluated for their ability to identify, from libraries of known inhibitors and modulators with decoys with similar physicochemical properties, γ-secretase inhibitors and modulators. Using these libraries, we defined strategies for identifying both γ-secretase inhibitors and modulators incorporating an initial pharmacophore-based screen followed by a docking-based screen, with each strategy employing distinct γ-secretase structures. Furthermore, known γ-secretase inhibitors and modulators were able to be identified from an external set of bioactive molecules following application of the derived screening strategies. The approaches described herein will inform the discovery of novel small molecules targeting γ-secretase.

Indexed as

Models, MolecularAmyloid Precursor Protein SecretasesDrug DiscoveryGamma Secretase Inhibitors and ModulatorsHumansMolecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureReproducibility of ResultsStructure-Activity RelationshipAmyloid Precursor Protein SecretasesGamma Secretase Inhibitors and ModulatorsAlzheimer’s diseasemolecular dockingpharmacophore modelvirtual screeningγ-secretase

Identifiers

PMID35011410
PMCPMC8746326
OpenAlexW4200485596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.